Clinical Trial Update: Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation [Phase 2, Phase 3]

View source ↗

Summary

Pfizer's UK-390,957 was evaluated for efficacy and safety in men with premature ejaculation in Phase 2 and Phase 3 trials that have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premature Ejaculation

Drugs mentioned

• UK-390,957

Snippet

Sponsor: Pfizer | Conditions: Ejaculation | Phase 2, Phase 3 | Status: COMPLETED